To print: Select File and then Print from your browser's menu

Title: Diphenylcyclopropenone Effective For Treatment Of Recalcitrant Warts

URL: http://link.springer-ny.com/link/service/journals/
10227/contents/01/0050/s10227-001-0050-9ch002.html

J Cutan Med Surg 2002; 6(3): 214-217 "The Use of Diphenylcyclopropenone in the Treatment of Recalcitrant Warts"
06/25/2002 06:40:48 PM
By James Adams

Topical immunotherapy with diphenylcyclopropenone is an effective treatment for recalcitrant palmoplantar and periungual warts. It should be considered as first-line treatment because of its high response rate, absence of scarring and painless application, according to investigators from the University of Alberta in Edmonton, Alberta, Canada. The researchers evaluated diphenylcyclopropenone in a seven-year retrospective review during which 90 male and 121 female patients were sensitized. The patients were between five and 78 years old, and completed an average of five treatments over a six-month period. One hundred and fifty four patients were included in the final study. Of the original 211 patients, 23 were lost to follow-up, four were undergoing treatment at the time of evaluation, one failed sensitization, one became pregnant, four discontinued because of side effects, three discontinued because of financial reasons, 18 discontinued before completing the required number of applications and three had additional treatment during diphenylcyclopropenone therapy and were excluded. One hundred thirty five of the 154 remaining patients (87.7 per cent) had complete clearance of warts. Treatment was very well-tolerated by the majority of the patients. Adverse events were local with pruritus in 15.6 per cent, blistering in 7.1 per cent and eczematous reactions in 14.2 per cent of the patients. A single patient developed local impetigo.

http://link.springer-ny.com/link/service/journals/
10227/contents/01/0050/s10227-001-0050-9ch002.html

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.